Objective-Nontranscriptional signaling mechanisms mediate some of the biological effects of estrogen, such as the rapid actions on the blood vessels. By interacting with phosphatidylinositol 3-kinase (PI3K), estrogen receptor (ER) ␣ leads to activation of protein kinase Akt and to subsequent increase in endothelial nitric oxide synthase activity. Because PI3K is mainly a cytoplasmic complex, we studied the cellular site of interaction between this enzyme and ER␣, and we dissected the molecular mechanisms that mediate this interaction. Methods and Results-By using cultured human saphenous vain endothelial cells, we found that cell membrane-bound ER␣ colocalizes with PI3K and may be responsible for PI3K activation. Furthermore, we characterized the subsequent steps in the activation of the PI3K/Akt signaling cascade, comparing the molecular events that follow insulin or estradiol activation of PI3K.
the transcriptional control of target genes via the binding of nuclear estrogen receptors to genomic consensus sequences. 1 Nonetheless, in the past few years, several biological actions of estrogen have been identified that are too rapid to be compatible with transcriptional mechanisms. 2 Estrogen has cardiovascular protective effects that largely depend on nontranscriptional regulation of the vessel wall. 3, 4 The most prominent nongenomic action of estrogen at this level is the induction of rapid vasorelaxation, which partially depends on the modulation of cell membrane ion channels in endothelial and smooth muscle cells. In vascular smooth muscle cells (VSMCs), estradiol treatment inhibits voltage-dependent L-type Ca 2ϩ channels. 5 17␤-estradiol also controls potassium efflux in VSMCs by opening Ca 2ϩ -and voltage-activated K ϩ channels via cGMP-dependent phosphorylation. 6 However, a major role is played by acute activation of NO synthesis in endothelial cells, 7, 8 which mediates estrogen effects also in humans. 9 Rapid induction of NO synthesis by estrogen largely depends on activation of the endothelial isoform of NO synthase (eNOS). 10 Estrogen receptor (ER) ␣ is involved in this phenomenon, which is in part attributable to mitogen-activated protein (MAP) kinases or tyrosine kinase activation. 7 In addition, we recently described the interaction of ER␣ with phosphatidylinositol 3-kinase (PI3K), showing that this mecha-nism accounts for the major part of eNOS activation in human endothelial cells. 8 Moreover, in a mice model, estrogen decreases vascular leukocyte accumulation after ischemia/reperfusion injury in an eNOS-, PI3K-, and ER-dependent manner, 8 and nongenomic recruitment of PI3K has marked anti-ischemic effects in a myocardial infarction model, 11 confirming the pathophysiological importance of this nongenomic pathway.
PI3K is a lipid kinase mediating the cellular effects of cell membrane-bound receptor-dependent molecules. 12 PI3K is predominantly a heterodimer formed by an 85-kDa (p85␣) adapter/ regulatory subunit and by a 110-kDa (p110) catalytic subunit. 13 By phosphorylating the D-3 position of the phosphatidylinositol ring, PI3K synthesizes phosphatidylinositol 3-phosphates (PtdIns-3-P, PtdIns-3,4-P 2 , PtdIns-3,4,5-P 3 ), 12 which regulate the activity of kinases containing pleckstrin homology domains such as phosphatidylinositol-dependent kinases and protein kinase Akt. 14, 15 The serine/threonine kinase Akt represents the principal downstream effector of PI3K, triggering several of its cellular effects, including activation of eNOS. 16, 17 The site of interaction between PI3K and ER␣ is unclear. Because PI3K is mainly cytoplasmic, it may be possible that cytoplasmic or cell membrane-bound ERs are responsible for the recruitment of PI3K. Indeed, extranuclear ERs have been described long since, 18 and, very recently, membrane-bound ERs have been identified in endothelial cells and implicated in the regulation of NO production. 19 Moreover, there is lack of information on the specific molecular mechanisms that link PI3K activation to interaction with ER␣ and on the signaling apparatus that is recruited by estrogen.
The aim of this study was therefore to characterize the subcellular site of interaction of ER␣ and PI3K as well as the specific mechanisms through which ER couples to and transactivates PI3K.
Methods

Cell Cultures
Human saphenous and bovine aortic endothelial cells (BAECs) were harvested with type IA collagenase. MCF-7 cells were from ATCC, and p85␣ ϩ/ϩ mice fibroblasts were a gift of Dr L. Cantley. All cells were cultured and stimulated under serum-starved conditions consisting of phenol red-free medium 199 or DMEM (Gibco BRL, Life Technologies) with 0.4% charcoal-stripped FCS.
Nitrite and eNOS Activity Assays
NO accumulation was determined by a modified nitrite assay using 2,3-diaminonaphthalene, as described. 8 Endothelial cells were harvested in PBS containing 1 mmol/L EDTA, and cell lysates were assayed for eNOS activity, as described. 8
Immunoprecipitations and PI3K Assays
Endothelial cell protein extracts were immunoprecipitated with Abs versus progesterone receptor (Santa Cruz, clone C-20), IRS-1 (Santa Cruz, clone E-12) or IRS-2 (Santa Cruz, clone M-19), ER␣ (Neo-Markers, clone TE111), eNOS (Transduction Laboratories, clone 3) or p85␣ (Pharmingen, clone U15), as described. 8 The immunoprecipitates were either used for immunoblotting or for PI3K assays, as described. 8 The labeled phospholipids were extracted with chloroform/methanol, and the organic phase, containing the PI3K products, was separated by borate TLC according to Walsh. 20 Immunoblotting Endothelial cell lysates were separated by SDS-PAGE, and immunoblottings were performed with standard technique. The Abs used were progesterone receptor (Santa Cruz, clone C-20), p85␣ (Pharmingen, clone U15), P-Tyr (Santa Cruz, clone PY99), G␣ q (Santa Cruz, clone E-17), Sp1 (Santa Cruz, clone PEP 2), ER␣ (NeoMarkers, clone TE111), wild-type Akt (catalogue No. 06-558) and Thr 308 -P-Akt ( 
Cell Immunofluorescent Analysis
Endothelial cells were fixed with 3% paraformaldehyde. Cells were incubated overnight with anti-p85␣ antibody (Pharmingen, clone U15, 1:50 in 1% BSA) and mouse anti-ER␣ (NeoMarkers, clone TE111, 1:50 in 1% BSA) at 4°C. Immunofluorescent staining was then performed as described. 21
Transfection Assays
The Akt constructs have been described previously. 22 BAECs and murine wild-type fibroblasts were transfected using the Lipofectamine reagent (Gibco BRL). To control for transfection efficiency, pCMV.␤-Gal plasmid containing the ␤-galactosidase gene was cotransfected in all experiments. ␤-galactosidase staining indicated that transfection efficiency was 30% to 35%. Cells (60% to 70% confluent) were assayed for eNOS and ␤-galactosidase activities as described. 8
Statistical Analysis
All values are expressed as meanϮSD. Statistical differences between mean values were determined by ANOVA, followed by the Fisher's protected least-significance difference test for comparison of mean values. Two-group comparisons were performed by the unpaired Student's t test.
A detailed Methods section is available online at http://atvb.ahajournals.org.
Results
In human endothelial cells, physiological concentrations of 17␤-estradiol (E 2 ) acutely increase NO release via an ER and PI3K-dependent mechanism. 8 Different from insulindependent activation, type III NOS is recruited in a biphasic manner (EC 50 value of Ϸ0.1 nmol/L), showing an early induction within 2 minutes, followed by a more substantial increase after 15 to 20 minutes ( Figure 1A ). The initial increase is mediated by tyrosine kinases and MAP kinases, 7 because it is partially prevented by genistein or by PD 98059 ( Figure 1B ), whereas the later increase can be blocked by wortmannin ( Figure 1B Because many effects of estrogen depend on transcriptional regulation, we investigated the effect of RNA synthase inhibitors, actinomycin D and 5,6dichlorobenzimidazole riboside (DRB), and protein synthesis inhibitor, cycloheximide, on estrogen-induced eNOS activity. Actinomycin D, DRB, or cycloheximide have no effect on basal or E 2 -stimulated eNOS activity (Figure IB, available online at http://atvb.ahajournals.org). Furthermore, the inhibitors have no effect on eNOS activation by insulin ( Figure  IB ) or acetylcholine (data not shown), pathways that do not involve transcriptional or translational mechanisms. 23, 24 Using a promoter construct containing a tandem estrogen-response element linked to a luciferase gene, we found that although actinomycin D does not block estrogen-stimulated eNOS activity, it blocks estrogen-induced gene transcription ( Figure IC , available online at http://atvb.ahajournals.org), suggesting that E 2 activates eNOS through nontranscriptional mechanisms. E 2 increases PI3K activity, with the greatest increase occurring after 20 minutes. 8 The increase in ER␣-associated PI3K is linked to increased association between ER␣ and the adapter/ regulatory subunit p85␣ ( Figure IIA ). This interaction is specific for ER␣, because no p85␣ coimmunoprecipitation can be detected with progesterone receptor ( Figure IIB) . Estrogen induces ER␣-p85␣ interaction similarly to insulin-triggered association between the phosphotyrosine adapter insulin receptor substrate-1 (IRS-1) and p85␣ ( Figure 2A ). However, ER␣-p85␣ interaction is not mediated by IRS-1 or IRS-2, because estrogen treatment is not associated with IRS-1/2 tyrosine phosphorylation ( Figure 2B ).
Estrogen-dependent ER␣-p85␣ interaction is associated with activation of ER␣-bound PI3K. 8 However, only a minority of PI3K associates with ER␣. In fact, we did not detect changes in PI3K activity in the total p85␣ immunoprecipitates, as opposed to ER␣ coimmunoprecipitates ( Figure IIC) . In agreement with the data on eNOS, PI3K activation by E 2 is independent of gene transcription or protein synthesis, as shown with DRB and cycloheximide ( Figure IID) . Confirming the immunoprecipitation studies, E 2 does not recruit PI3K via IRS-1/2, because no activation of IRS-1/2-associated PI3K can be seen on estrogen challenge ( Figure 2C ). Furthermore, insulin is unable to trigger the activation of ER␣-associated PI3K, nor to increase estrogeninduced PI3K activation ( Figure 2D ), suggesting that the 2 hormones recruit PI3K through distinct mechanisms.
Because ERs are prevalently localized in the nucleus, whereas PI3K is mainly cytoplasmic, the site of interaction is unclear.
ER␣ staining in untreated cells is mostly nuclear, but after E 2 treatment, ER␣ staining in the cytoplasmic/cell membrane compartment increases ( Figures 3A and 3B ) time-consistently with eNOS and PI3K activation.
Accumulation of ER␣ in the cytoplasm/cell membrane is prevented by tamoxifen ( Figures 3A and 3B ) and seems to be a feature of endothelial cells, because it is not detectable in MCF-7 cells in similar conditions ( Figure 3B ). PI3K staining is not affected by E 2 , but E 2 favors the colocalization of ER␣ and p85␣ in the cytoplasmic/cell membrane compartment ( Figure 3A) , although a nuclear interaction cannot be completely excluded by these experiments. To confirm these observations, we obtained purified nuclear and cytoplasmic/cell membrane fractions from endothelial cells and studied the distribution of ER␣ and p85␣. The purity of the fractions was confirmed by immunoblotting for the cell membrane-associated G␣ q and for the nuclear transcription factor Sp1. ER␣ is mainly nuclear, but there is a slight enhancement of the cytoplasmic/cell membrane distribution after E 2 treatment ( Figure 3C ). p85␣, instead, is mainly cytoplasmic, and its distribution does not change with exposure to estrogen ( Figure 3C ).
Because cell membrane ERs have been described in endothelial cells, and they have been involved in eNOS regulation, 19 we studied whether the membrane-impermeable E 2 -BSA complex was able to activate eNOS. Compared with E 2 , E 2 -BSA is still able to activate eNOS, but the kinetics are slightly different ( Figure 3D ). Indeed, the early eNOS activation, which is sensitive to MAP kinase inhibitors, is comparable, but the later, wortmannin-sensitive increase is reduced ( Figure 3D ). From these experiments, there is evidence that cell membrane-bound estrogen receptors are important for binding and activation of PI3K.
One of the prominent downstream targets of PI3K is phosphorylation and activation of protein kinase Akt by phosphatidyl-dependent kinase (PDK)-1 and -2. 14, 15 Estrogen increases Akt kinase activity, 8 but the mechanism is unclear. Akt is activated by 2 independent phosphorylations on serine 473 15 and threonine 308 . 14 Under basal conditions, there is little threonine or serine phosphorylation of Akt ( Figure 4A ). E 2 causes Akt threonine and serine phosphorylation in a time-delayed manner similar to E 2 -stimulated PI3K and eNOS activation. Phosphorylation of Akt by E 2 is inhibited by wortmannin and ICI 182,780 ( Figures 4A) . These results demonstrate that activation of PI3K by ER␣ is associated with phosphorylation of Akt, which represents the mechanism for Akt activation by estrogen. To understand if Akt phosphorylation may happen in the microenvironment of a complex involving ER␣ and PI3K, we performed immunoprecipitations for these 2 latter molecules and examined A and B, HSVECs (A and B) and MCF-7 (B) cells were stimulated with E 2 (10 nmol/L) with and without tamoxifen (TM, 1 mol/L), and immunofluorescent staining using antibodies to ER␣ (FITC, green) or p85␣ (rhodamine, red), alone or in combination, was performed. Note that between 10 and 20 minutes after E 2 stimulation, there is increased ER␣ staining in the cytoplasm/cell membrane of endothelial cells, where it colocalizes with p85␣ (arrows), whereas this does not happen in MCF-7 cells (B). C, Purified cytoplasmic/cell membrane or nuclear protein extracts from HSVECs treated with E 2 (10 nmol/L) or with vehicle (ethanol) were immunoblotted for the membrane-associated G protein G␣ q , for the nuclear-associated Sp1, for ER␣ or for p85␣. D, Effect of cell membrane impermeable BSA-conjugated E 2 (E 2 -BSA) ( whether Akt coprecipitates with them. Our results show that this is not the case ( Figure IIIA ), suggesting that Akt phosphorylation and eNOS activation take place as separate processes respect to ER␣/PI3K interaction. This hypothesis is additionally supported by the evidence that ER␣ and p85␣ do not associate with eNOS in basal conditions nor after E 2 treatment ( Figure  IIIB) .
Akt mediates eNOS activation by estrogen, 8 as confirmed by the transient transfection of BAECs and murine fibroblasts with Akt mutant constructs. BAECs express both ER␣ and eNOS, and the p85␣ ϩ/ϩ fibroblasts were cotransfected with ER␣ and eNOS cDNAs. The transfection of the wild-type form of Akt or of the two myristylated, constitutively active Akt mutants (myr-Akt and ⌬PH-myr-Akt [deletion of the pleckstrin homology domain]) markedly increased eNOS activity ( Figure IIIC) . Transfection of a kinase-inactive dominant-negative Akt mutant with a point mutation in the ATP binding domain, Akt (K179M), 22 does not affect basal eNOS activity but decreases E 2 -stimulated eNOS activity by 50% ( Figure IIIC) , compatible with transfection efficiency. Because transfection experiments require longer periods of incubations in the presence of the constructs, we checked whether transfection itself may be inducing eNOS or iNOS expression or alter ER␣ or p85␣ levels. BAECs overexpressing the different Akt constructs have unchanged amounts of ER␣, p85␣, and eNOS, and no expression is present for iNOS in any condition ( Figure 4B) . These experiments confirm that acute regulation of eNOS by Ser/Thrphosphorylated Akt accounts for the rapid production of NO after estrogen treatment in endothelial cells.
Discussion
The role of cell membrane-bound estrogen receptors has been discussed for several years, since the first identification of membrane binding sites for 17␤-estradiol. 18 Since then, estrogen receptors localized on the cell membrane have been proposed to be involved with the transduction of the nongenomic effects of estrogen, that is with that variety of actions that estrogen exerts in different tissues, which are too rapid to be compatible with gene transcription and protein synthesis. Nonetheless, there is still uncertainty about the real nature of these receptors, as well as about the signaling mechanisms that they activate on binding with estrogen. 25 Several intracellular signaling cascades have been associated with rapid estrogen-dependent effects: the adenylate cyclase pathway, 26 the phospholipase C pathway, 27 the G-proteincoupled receptor-activated pathways, 28 as well as the MAP kinase pathway. 29 At the vascular level, cell-surface ERs have been proposed to mediate estrogen-dependent rapid activation of NO synthesis, 19, 30 and this seems to be partially dependent on MAP kinase activation. 30 We have shown that rapid eNOS regulation by estrogen in endothelial cells is played through modulation of the PI3K/Akt pathway via a direct interaction of ER␣ with the regulatory subunit of PI3K, p85␣. 8 Our present data add to these findings, defining a role for cell-membrane estrogen receptors as the potential subpopulation of ERs that interacts with PI3K. These findings significantly broaden the role of cell membrane ERs, potentially involving these receptors with a variety of intracellular activities triggered by this lipid kinase. 12, 31, 32 The debate is open on the origin of cell membrane ERs. Recently, transfection studies have shown that nuclear and cell membrane ERs derive from the same transcripts, 28 but still no data are available on possible conformational differences between these subpopulations. We have shown that ER␣ interacts with p85␣ after a conformational change dependent on estradiol binding and that this phenomenon does not require adapter molecules. 8 Our present data show that BSA-conjugated E 2 activates eNOS through PI3K/Akt. However, we find differences in the profile of eNOS activation when comparing the effects of E 2 -BSA versus natural E 2 . A possible explanation may be that the steric hindrance imposed by the BSA may partially prevent the association between the engaged ER␣ and p85␣, supporting the concept that, as for ER-dependent nuclear effects, a correct conformational change on ligand binding is necessary for the nongenomic signaling of cell membrane-bound ERs. Alternatively, it may be that part of the ER␣/PI3K interaction takes place in the cytoplasm, and therefore E 2 -BSA may be less potent than E 2 because of lack of recruitment of non-membranebound cytoplasmic ER␣.
An intriguing finding is the apparent increase in the ER␣ amount in the cytoplasm after estradiol exposure in endothelial but not MCF-7 cells. Although the mechanisms that regulate steroid receptors cytoplasmic/nuclear shuttling are not completely clear, there are hints that interaction with specific coactivators or the phosphorylation status of RNA polymerase II C-terminal domain may induce cyclic assembly and disassembly of ER transcription complexes in the nucleus, 33 therefore inducing ER cycling on and off the nucleus, which may possibly serve to create a frequent sampling of the extracellular hormonal milieu. 33 If this is the case, cell-specific coactivators may induce preferential ER cytoplasmic or nuclear localization and may provide the basis for the different relevance of nongenomic versus genomic signaling of ER␣ in distinct tissues.
We provide evidence that ER␣ recruits PI3K independently by adapter molecules mediating insulin signaling, such as IRS-1/2 or by tyrosine kinases pathways, therefore additionally characterizing the molecular events that link ER␣ to PI3K. We also show that interaction with PI3K is specific for ER␣ and does not extend to progesterone receptor. ER␤ does not interact with PI3K, 8 as well, and this reinforces the possibility that the two isoforms may have partially distinct roles in some tissues, such as the vascular wall. This has been previously shown using vascular injury models, where estrogen protective effects are entirely mediated by ER␣, 34 although ER␤ (and not ER␣) expression increases steeply after the injury, 35 suggesting distinct roles for the 2 receptors. The differential interaction with PI3K may therefore represent the first example of the different role of ER␣ and ER␤ on nongenomic signaling pathways.
When looking at the amount of PI3K activated by ERs, it turns out that the recruitment of a small fraction of total PI3K is sufficient to give rise to the visible regulatory effects that ensue on estrogen treatment of endothelial cells (ie, eNOS activation and NO release). This is strongly suggested by the fact that modulation of ER␣-mediated PI3K activity is not discernible in p85␣-immunoprecipitates, because of the high basal activity contributed by total cellular PI3K. Thus, because most of PI3K is potentially active and resides in the cytoplasm under basal conditions, ER␣-associated PI3K must have some specificity to activate the signal for eNOS activation. A possible explanation for this may be represented by the localization to the cell membrane of the ER subpopulation, which may favor signal transduction to eNOS.
Localization to the cell membrane may also facilitate rapid activation of Akt, which is responsible for estrogen-dependent eNOS activation. Indeed, PtdIns-3,4,5-P 3 production by PI3K depends on the local availability of lipid substrates, which is maximal at the cell membrane and is necessary for the activation of PDK-1 and -2. These 2 kinases mediate the serine and threonine phosphorylation of Akt. 14, 15 We show that estrogendependent activation of Akt through PI3K is mediated through phosphorylation on these residues, suggesting that the localization of ERs to cell membrane and their recruitment of PI3K may create a microenvironment at this site that facilitates eNOS activation (which is prevalently localized to the cell membrane, as well) by activated Akt.
In conclusion, our experiments provide evidence for an important role of cell membrane-bound estrogen receptors for binding and activation of PI3K, which leads to eNOS activation. These findings suggest an important function for the extranuclear fraction of estrogen receptors in mediating rapid, nontranscriptional signaling of estrogen.
